Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma

L Wu, Y Ge, Y Yuan, H Li, H Sun, C Xu, Y Wang… - Cancer Letters, 2022 - Elsevier
Gemcitabine (GEM) resistance is one of the major causes of treatment failure in pancreatic
ductal adenocarcinoma (PDAC) in clinic. Here, through CRISPR/Cas9 activation library …
被引用次数：11 相关文章

Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.

L Wu, Y Ge, Y Yuan, H Li, H Sun, C Xu, Y Wang… - Cancer Letters, 2022 - europepmc.org
Gemcitabine (GEM) resistance is one of the major causes of treatment failure in pancreatic
ductal adenocarcinoma (PDAC) in clinic. Here, through CRISPR/Cas9 activation library …

Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma

L Wu, Y Ge, Y Yuan, H Li, H Sun, C Xu… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Gemcitabine (GEM) resistance is one of the major causes of treatment failure in pancreatic
ductal adenocarcinoma (PDAC) in clinic. Here, through CRISPR/Cas9 activation library …